Although EGFR-TKI combination treatment for patients with advanced NSCLC with EGFR-sensitive mutations is extensively studied, so far, no accurate and effective prognostic biomarker has been established in this setting, which represents an unmet clinical need. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.